Literature DB >> 10820360

Onycholysis as a complication of systemic chemotherapy: report of five cases associated with prolonged weekly paclitaxel therapy and review of the literature.

S Hussain1, D N Anderson, M E Salvatti, B Adamson, M McManus, A S Braverman.   

Abstract

BACKGROUND: Onycholysis has been reported in association with the use of several noncytotoxic drugs and with chemotherapy in 135 patients. Onycholysis may be precipitated by exposure to ultraviolet radiation.
METHODS: The authors studied 91 patients who received paclitaxel and 187 patients who received doxorubicin.
RESULTS: Onycholysis occurred in 5 of 21 patients who received > 6 courses of weekly paclitaxel, developing in the summer months in all 5 patients. It did not occur in patients who received fewer weekly paclitaxel courses or those who were treated every 3 weeks. Onycholysis did not occur in 187 patients who received doxorubicin. Review of the literature revealed that onycholysis is nearly exclusively associated with anthracycline and taxane therapy.
CONCLUSIONS: Prolonged weekly paclitaxel, other taxanes, and anthracyclines cause onycholysis in some patients, which may be precipitated by exposure to sunlight. Patients receiving these drugs should protect their nails from sunlight.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10820360     DOI: 10.1002/(sici)1097-0142(20000515)88:10<2367::aid-cncr22>3.0.co;2-#

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  17 in total

1.  Severe skin toxicity observed with the combination of capecitabine and weekly paclitaxel in metastatic breast cancer patients.

Authors:  Snezana Susnjar; Snezana M Bosnjak; Sinisa Radulovic
Journal:  Support Care Cancer       Date:  2008-09-05       Impact factor: 3.603

Review 2.  Dermatological adverse events with taxane chemotherapy.

Authors:  Vincent Sibaud; Nicole R Lebœuf; Henri Roche; Viswanath R Belum; Laurence Gladieff; Marion Deslandres; Marion Montastruc; Audrey Eche; Emmanuelle Vigarios; Florence Dalenc; Mario E Lacouture
Journal:  Eur J Dermatol       Date:  2016-10-01       Impact factor: 3.328

Review 3.  Drug-induced photosensitivity: culprit drugs, management and prevention.

Authors:  Aaron M Drucker; Cheryl F Rosen
Journal:  Drug Saf       Date:  2011-10-01       Impact factor: 5.606

4.  Nail changes due to docetaxel--a neglected side effect and nuisance for the patient.

Authors:  Dorte Winther; Ditte Marie Saunte; Marianne Knap; Vera Haahr; Anders Bonde Jensen
Journal:  Support Care Cancer       Date:  2007-02-22       Impact factor: 3.603

5.  A randomised controlled trial of interventions for taxane-induced nail toxicity in women with early breast cancer.

Authors:  Audrey Morrison; Rebecca Marshall-McKenna; Angus K McFadyen; Cathy Hutchison; Ann-Marie Rice; Lynne Stirling; Pauline McIlroy; Iain R Macpherson
Journal:  Sci Rep       Date:  2022-07-07       Impact factor: 4.996

6.  Polydactylous Photo-Onycholysis in a Patient of Breast Carcinoma.

Authors:  Thammannagowda Prarthana; Hitaishi Mehta; Siddhant Khare; Keshavamurthy Vinay
Journal:  Indian Dermatol Online J       Date:  2022-06-24

7.  Docetaxel-induced nail changes--a neurogenic mechanism: a case report.

Authors:  Gunnar Wasner; Felix Hilpert; Jörn Schattschneider; Andreas Binder; Jacobus Pfisterer; Ralf Baron
Journal:  J Neurooncol       Date:  2002-06       Impact factor: 4.130

8.  Acute felon as a complication of systemic paclitaxel therapy: case report and review of the literature.

Authors:  John B Hijjawi; David G Dennison
Journal:  Hand (N Y)       Date:  2007-04-13

Review 9.  Drug-induced skin, nail and hair disorders.

Authors:  Laurence Valeyrie-Allanore; Bruno Sassolas; Jean-Claude Roujeau
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

10.  Chemotherapy-induced dermatological toxicity: frequencies and impact on quality of life in women's cancers. Results of a prospective study.

Authors:  Mark Hackbarth; Norbert Haas; Christina Fotopoulou; Werner Lichtenegger; Jalid Sehouli
Journal:  Support Care Cancer       Date:  2007-08-07       Impact factor: 3.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.